echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Kang Cai|Annual report net profit: Zhongsheng United lost 58 million yuan Yiling Pharmaceutical 1.22 billion Yisheng Pharmaceutical 79.4 million

    Kang Cai|Annual report net profit: Zhongsheng United lost 58 million yuan Yiling Pharmaceutical 1.22 billion Yisheng Pharmaceutical 79.4 million

    • Last Update: 2021-03-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Original title: Kang Cai | Annual report net profit: Zhongsheng United lost 58 million yuan Yiling Pharmaceutical 1.


    Zhongsheng United's loss in 2020 narrows

    Zhongsheng United's loss in 2020 narrows Zhongsheng United's loss in 2020 narrows

    Zhongsheng United (03332) issued an announcement that the group's revenue as of 2020 is expected to decrease by about 8% compared with that of 2019.


    Zhongsheng United (03332) issued an announcement that the group's revenue as of 2020 is expected to decrease by about 8% compared with that of 2019.


    The company stated that in 2020, the COVID -19 epidemic will have a greater impact on the sales revenue of Living Nature Natural Products Limited.


    Yisheng Pharmaceutical's 2020 net profit is about 79.


    On February 25, Yisheng Pharmaceutical released the 2020 annual results bulletin.


    Mainly due to the impact of the new crown pneumonia epidemic during the reporting period, the company's main market terminal hospitals and franchised beauty salons and other offline channels were affected to a certain extent, resulting in a decrease in the company's operating income from the same period last year.


    Yiling Pharmaceutical: 2020 net profit of approximately 1.


    On February 25, Yiling Pharmaceutical released the 2020 annual results bulletin.


    The increase in the company’s total operating income in 2020 is mainly due to the significant increase in the brand awareness of the company’s Lianhua Qingwen products during the reporting period, a significant increase in domestic market demand, and sales in more than ten registered overseas countries.


    Blue Crystal Microbes completed nearly 200 million yuan in Series B financing

    On February 26, Bluepha announced the completion of a Series B financing of nearly RMB 200 million.


    On February 26, Bluepha announced the completion of a Series B financing of nearly RMB 200 million.


    Established in 2016, Kyanite Microbe is a start-up company engaged in molecular and material innovation based on synthetic biotechnology.


    Livzon Biotech obtains the new "Business License".
    Livzon Biotech’s shareholders are changed to the company, Joincare, YF Pharmab Limited (YF) and Hainan Lisheng Juyuan Investment Partnership (Limited Partnership), and Livzon Bio’s registered capital is increased to RMB 889 million.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.